Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Nuria Mulet"'
Autor:
Elena Elez, Chiara Chianese, Enrique Sanz‐García, Erica Martinelli, Alba Noguerido, Francesco Mattia Mancuso, Ginevra Caratù, Judit Matito, Julieta Grasselli, Claudia Cardone, Riziero Esposito Abate, Giulia Martini, Cristina Santos, Teresa Macarulla, Guillem Argilés, Jaume Capdevila, Ariadna Garcia, Nuria Mulet, Evaristo Maiello, Nicola Normanno, Frederick Jones, Josep Tabernero, Fortunato Ciardello, Ramon Salazar, Ana Vivancos
Publikováno v:
Molecular Oncology, Vol 13, Iss 9, Pp 1827-1835 (2019)
Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS‐mutant allele fraction (MAF) in plasma in mCRC. Forty‐seven plasma sampl
Externí odkaz:
https://doaj.org/article/3ba50329631d4c038cfdd0a1c4537257
Autor:
Javier Ros, Iosune Baraibar, Emilia Sardo, Nuria Mulet, Francesc Salvà, Guillem Argilés, Giulia Martini, Davide Ciardiello, José Luis Cuadra, Josep Tabernero, Elena Élez
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characteriz
Externí odkaz:
https://doaj.org/article/1009baa5d178419fb4f5aad0d5c307e2
Autor:
Giulia Martini, Rodrigo Dienstmann, Javier Ros, Iosune Baraibar, Jose Luis Cuadra-Urteaga, Francesc Salva, Davide Ciardiello, Nuria Mulet, Guillem Argiles, Josep Tabernero, Elena Elez
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several molecular alterations that confer resistance to standard chemotherapy and targeted agents. Mecha
Externí odkaz:
https://doaj.org/article/6654e5c3559c4202a4a19cbc5b7e1603
Autor:
Marc Oliva, Nuria Mulet-Margalef, Maria Ochoa-De-Olza, Stefania Napoli, Joan Mas, Berta Laquente, Laia Alemany, Eric J. Duell, Paolo Nuciforo, Victor Moreno
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 3, p 1446 (2021)
The study of the human microbiome in oncology is a growing and rapidly evolving field. In the past few years, there has been an exponential increase in the number of studies investigating associations of microbiome and cancer, from oncogenesis and ca
Externí odkaz:
https://doaj.org/article/fa60c90251e7438ea21321a4e1e8cd2f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jose Luis Cuadra-Urteaga, Nuria Mulet, Javier Ros, Elena Elez, Iosune Baraibar, Nadia Saoudi Gonzalez, Josep Tabernero, A. Valdivia, Francesc Salvà, D. Marmolejo
Publikováno v:
Expert Opinion on Biological Therapy. 21:1315-1324
Introduction: Colorectal cancer (CRC) is a major public health problem. Despite major progress understanding the biological basis of this tumor added to the incorporation of optimized diagnostic an...
Autor:
Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, José M. Viéitez, Cristina Grávalos, Pilar García-Alfonso, Cristina Santos, María Tobeña, Beatriz García-Paredes, Manuel Benavides, María T. Cano, Fotios Loupakis, Mercedes Rodríguez-Garrote, Fernando Rivera, Richard M. Goldberg, Chiara Cremolini, Jaafar Bennouna, Fortunato Ciardiello, Josep M. Tabernero, Enrique Aranda, Josep Tabernero, Alfredo Falcone, Richard Goldberg, null Argilés, J. Tabernero, N. Mulet, M.L. Limón, M. Valladares, P. Jiménez, J. Ma Vieitez, C. Grávalos, P. García-Alfonso, C. Santos, D. Páez, M. Tobeña, J. Sastre, B. García Paredes, M. Benavides, E. Aranda, M.T. Cano, F. Loupakis, M. Rguez Garrote, C. Guillén, Ma F. Rivera, J. Safont, S. Hiret, J. Bennouna, D. Pannier, D. Malka, A. Falcone, C. Cremolini
Publikováno v:
Scientia
Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients.Patients and methods: Patients with mCRC and progression during or within 3 months
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bd05f70988e5ca895198e0724218256
https://hdl.handle.net/11591/486122
https://hdl.handle.net/11591/486122
Autor:
Nuria Mulet, Guillem Argiles, Elena Elez, Alba Noguerido, Josep Tabernero, Ignacio Matos, Javier Ros
Publikováno v:
Expert Opinion on Investigational Drugs. 28:463-471
INTRODUCTION The addition of monoclonal antibody (mAb) epidermal growth factor receptor (EGFR) inhibitors to classic chemotherapy doublet backbones has improved survival of metastatic colorectal cancer (mCRC). However, the role of triple-drug chemoth
Autor:
Roser López-Alemany, Santi Rello-Varona, Nuria Mulet-Margalef, Xavier Garcia del Muro, Oscar M. Tirado, Miriam Fuentes-Guirado, Silvia Garcia-Monclús, Aida Contreras-Pérez
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-15 (2019)
Dipòsit Digital de la UB
Universidad de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
Soft-tissue sarcomas (STS) are an uncommon and heterogeneous group of malignancies that result in high mortality. Metastatic STS have very bad prognosis due to the lack of effective treatments. Dinaciclib is a model drug for the family of CDK inhibit
Autor:
Juan José Soto, Carlos Erasun Lecuona, Sandra Llop Serna, Nuria Mulet Margalef, Agostina Stradella, Rafael Villanueva, Mariona Calvo Campos, Maria Jove Casulleras, Carmen Cuadra Amor, Ramon Salazar Soler, Marta Gil-Martin, Juan Martin-Liberal, Marc Oliva
Publikováno v:
Journal of Clinical Oncology. 40:2581-2581
2581 Background: The overall survival (OS) benefit observed with immune checkpoint inhibitors led to their approval in many tumor types. Given the large number of IT compounds in early clinical development, many pts are offered IT within Ph1-CT even